NeuroVive Pharmaceutical AB Kapitalrendite
Was ist das Kapitalrendite von NeuroVive Pharmaceutical AB?
Kapitalrendite von NeuroVive Pharmaceutical AB ist -69.63%
Was ist die Definition von Kapitalrendite?
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Kapitalrendite von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit kapitalrendite ähnlich NeuroVive Pharmaceutical AB
- Talga Resources hat Kapitalrendite von -69.77%
- Kinetiko hat Kapitalrendite von -69.76%
- SinoMab BioScience hat Kapitalrendite von -69.74%
- Rhino Resource Partners LP hat Kapitalrendite von -69.70%
- Haydale Graphene Industries plc hat Kapitalrendite von -69.66%
- Coppercorp Resources Inc hat Kapitalrendite von -69.65%
- NeuroVive Pharmaceutical AB hat Kapitalrendite von -69.63%
- Ether Capital hat Kapitalrendite von -69.63%
- Lions Bay Capital hat Kapitalrendite von -69.62%
- STRATA Skin Sciences Inc hat Kapitalrendite von -69.56%
- Dynamo Capital hat Kapitalrendite von -69.39%
- Mer Telemanagement Solutions hat Kapitalrendite von -69.37%
- Praxis Home Retail hat Kapitalrendite von -69.32%